8 reports

  • INORGANIC DEVELOPMENTS 11.5.1 OVERVIEW
  • 6.3 Performance of Key Players

Figure ##. ##.

  • Biotech Diagnostics
  • Diagnostics
  • Genetic Testing
  • Medical Biotechnology
  • Natera, Inc.
  • entered into an exclusive agreement with Natera to bring non-invasive prenatal testing (NIPT) to India.
  • 6.2 Market Positioning

Chromosomal analysis is one of the most frequently performed tests in the laboratory prenatal diagnostics.

  • Biotech Diagnostics
  • Diagnostics
  • Genetic Testing
  • Healthcare
  • Natera, Inc.
  • LIQUID BIOPSY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
  • NIPT MARKET SHARE ANALYSIS BY MAJOR PLAYERS (2017) (%)

Exosome Diagnostics is one of the major player which employs Exosome based liquid biopsy.

  • Cancer
  • Diagnostics
  • Genetic Testing
  • Healthcare
  • Natera, Inc.
  • Date
  • GUARDANT360 LIQUID BIOPSY PLATFORM.

PHONE: +## ##I##-##-## FAX: +## ##-##-## WEBSITE: WWW. CAREDX. COM ##. ##. ## OVERVIEW CAREDX, INC., A MOLECULAR DIAGNOSTIC COMPANY, DEVELOPS AND COMMERCIALIZES A DIAGNOSTIC SURVEILLANCE SOLUTION FOR TRANSPLANT RECIPIENTS.

  • Biotech Diagnostics
  • Diagnostics
  • DNA
  • Genetic Testing
  • Natera, Inc.
  • 3.3 SELECTED NON-INVASIVE PRENATAL DIAGNOSTIC PRODUCTS
  • ES.4 MARKET SHARE ANALYSIS: NON-INVASIVE PRENATAL DIAGNOSTICS

EXHIBIT E. S. ##: GLOBAL MARKET SHARE ANALYSIS - NON-INVASIVE PRENATAL DIAGNOSTIC PRODUCTS (2013) Sequenom Inc Ariosa Diagnostics BGI Diagnostics (Division of BGI) Natera, Inc.

  • Diagnostics
  • Genomics
  • Genomics Proteomics And Enabling Technology
  • Ariosa Diagnostics, Inc.
  • Natera, Inc.
  • NATERA INC, MAJOR PRODUCTS AND SERVICES
  • NATERA INC - MAJOR PRODUCTS AND SERVICES

## Colorectal Cancer ## Craniosynostosis ## Cystic Fibrosis ## Duchenne Muscular Dystrophy ## Fragile X Syndrome ## Achondroplasia ## Graft Versus Host Disease ## Hemoglobinopathy ## Lung Cancer ## Miscarriage

  • Diagnostics
  • Genetic Testing
  • United States
  • Company Financials
  • Natera, Inc.
  • Natera Inc, Deals By Market, 2012 to YTD 2018
  • Investor(s)

Fifty-one percent of approximately ##, ## tests were accessioned in the first quarter of 2017.

  • Diagnostics
  • Genetic Testing
  • Medical Device
  • Medical Equipment
  • Natera, Inc.
  • Natera Inc, Medical Devices Deals, 2012 to YTD 2018
  • May 04, 2017: Natera Announces the Appointment of Gail Marcus as Member of the Board of Directors

Marcus served as president and chief executive officer of Caris Diagnostics.

  • Diagnostics
  • Healthcare
  • United States
  • Company Financials
  • Natera, Inc.